VERU INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
VERU INC. (VERU) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $577.97 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- VERU INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $577.97K, a 65.38% decline year-over-year.
- VERU INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $402.71K, a 81.89% decline year-over-year.
- VERU INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $757.61K, a 71.67% decline year-over-year.
- VERU INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.67M, a 50.56% decline year-over-year.
- VERU INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $8.10M, a 40.62% decline from fiscal 2024.
- VERU INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $13.64M, a 23.85% decline from fiscal 2023.
- VERU INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $17.92M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $577.97K 10-Q · filed 2026-08-10 | $980.68K derived: sum of 2 quarters · filed 2026-08-10 | $1.74M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2026-03-31 | $402.71K 10-Q · filed 2026-08-10 | $1.16M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2025-12-31 | $757.61K 10-Q · filed 2026-08-10 | |||
| 2025-09-30 | $8.10M 10-K · filed 2025-12-17 | |||
| 2025-06-30 | $1.67M 10-Q · filed 2026-08-10 | $3.89M derived: sum of 2 quarters · filed 2026-08-10 | $6.57M derived: sum of 3 quarters · filed 2026-08-10 | |
| 2025-03-31 | $2.22M 10-Q · filed 2026-08-10 | $4.90M derived: sum of 2 quarters · filed 2026-08-10 | ||
| 2024-12-31 | $2.67M 10-Q · filed 2026-08-10 | |||
| 2024-09-30 | $13.64M 10-K · filed 2025-12-17 | |||
| 2024-06-30 | $3.38M 10-Q · filed 2025-08-12 | $7.01M derived: sum of 2 quarters · filed 2025-08-12 | $10.42M derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $3.63M 10-Q · filed 2025-08-12 | $7.04M derived: sum of 2 quarters · filed 2025-08-12 | ||
| 2023-12-31 | $3.41M 10-Q · filed 2025-08-12 | |||
| 2023-09-30 | $17.92M 10-K · filed 2024-12-16 | |||
| 2023-06-30 | $4.55M 10-Q · filed 2024-08-08 | $8.39M derived: sum of 2 quarters · filed 2024-08-08 | $13.23M derived: sum of 3 quarters · filed 2024-08-08 | |
| 2023-03-31 | $3.84M 10-Q · filed 2024-08-08 | $8.68M derived: sum of 2 quarters · filed 2024-08-08 | ||
| 2022-12-31 | $4.85M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |